Theravance Inc | The Truth About Skin Care

{ Tag Archives } Theravance Inc

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus [...]

Also tagged Adult Patients, Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Launch, Mrsa, Nasdaq, September 11, Skin And Skin, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Thrx, United States

2009 11 06 Skin Care News Comments Off

Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Also tagged Adult Patients, Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Fda Approval, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Mrsa, Nasdaq, Skin And Skin, Skin Infections, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Thrx

2009 09 14 Skin Care News Comments Off

FDA Accepts For Review Theravance’s Complete Response Submission For Telavancin For The Treatment Of Complicated Skin And Skin Structure Infections

Theravance, Inc. (NASDAQ: THRX) announced that the U.S. Food and Drug Administration (FDA) accepted as complete for review Theravance’s response to the February 2009 Complete Response letter, which outlined requirements for approval of telavancin for the treatment of complicated skin and skin structure infections (cSSSI).

Also tagged Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Nasdaq, Response Letter, Skin And Skin, Skin Infections, Skin Structure Infections, Submission, Telavancin, Thrx

2009 04 28 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Theravance Inc

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections

FDA Accepts For Review Theravance’s Complete Response Submission For Telavancin For The Treatment Of Complicated Skin And Skin Structure Infections

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: